Evidence map›Paper›PMID 36290026›Full record

ReviewAntibiotics (Basel, Switzerland)2022

The In Vivo and In Vitro Assessment of Pyocins in Treating

Abdulaziz Alqahtani, Jonathan Kopel, Abdul Hamood

Open access · goldAbstract readReview
In one paragraph

Review in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. R pyocin sensitivity ofJournal of medical microbiology · 2026
    Article
  3. Article
  4. Lipopolysaccharide-targeting treatments for multidrug-resistantExpert opinion on therapeutic targets · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Abdulaziz AlqahtaniClinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha 61321, Saudi Arabia.ORCID 0000-0002-2332-2593
Jonathan KopelDepartment of Immunology and Microbiology, Texas Tech University Health Sciences Center, Lubbock, TX 79763, USA.ORCID 0000-0001-5934-2695
Abdul HamoodDepartment of Immunology and Microbiology, Texas Tech University Health Sciences Center, Lubbock, TX 79763, USA.ORCID 0000-0001-7193-7827
Texas Tech University · USKing Khalid University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

infectionPseudomonaspyocintreatmentvirulence factors

Identifiers

PMID36290026
PMCPMC9598984
OpenAlexW4303579134

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.